ATE455556T1 - Zusammensetzung zur stabilisierung des corneagewebes während oder nach orthokeratologischem tragen von kontaktlinsen - Google Patents

Zusammensetzung zur stabilisierung des corneagewebes während oder nach orthokeratologischem tragen von kontaktlinsen

Info

Publication number
ATE455556T1
ATE455556T1 AT00965007T AT00965007T ATE455556T1 AT E455556 T1 ATE455556 T1 AT E455556T1 AT 00965007 T AT00965007 T AT 00965007T AT 00965007 T AT00965007 T AT 00965007T AT E455556 T1 ATE455556 T1 AT E455556T1
Authority
AT
Austria
Prior art keywords
composition
type
collogens
stabilizing
corneage
Prior art date
Application number
AT00965007T
Other languages
English (en)
Inventor
Dewoolfson H Bruce
Devore P Dale
Original Assignee
Bruce H Dewoolfson Irrevocable
Euclid Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce H Dewoolfson Irrevocable, Euclid Systems Corp filed Critical Bruce H Dewoolfson Irrevocable
Application granted granted Critical
Publication of ATE455556T1 publication Critical patent/ATE455556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G02C7/047—Contact lens fitting; Contact lenses for orthokeratology; Contact lenses for specially shaped corneae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Eyeglasses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT00965007T 1999-09-15 2000-09-15 Zusammensetzung zur stabilisierung des corneagewebes während oder nach orthokeratologischem tragen von kontaktlinsen ATE455556T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15395999P 1999-09-15 1999-09-15
US17380199P 1999-12-30 1999-12-30
PCT/US2000/025190 WO2001019386A2 (en) 1999-09-15 2000-09-15 Composition for stabilizing corneal tissue during or after orthokeratology lens wear

Publications (1)

Publication Number Publication Date
ATE455556T1 true ATE455556T1 (de) 2010-02-15

Family

ID=26851024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965007T ATE455556T1 (de) 1999-09-15 2000-09-15 Zusammensetzung zur stabilisierung des corneagewebes während oder nach orthokeratologischem tragen von kontaktlinsen

Country Status (10)

Country Link
EP (1) EP1218027B1 (de)
JP (2) JP4786095B2 (de)
KR (1) KR100720291B1 (de)
CN (1) CN1214815C (de)
AT (1) ATE455556T1 (de)
AU (1) AU7580200A (de)
DE (1) DE60043736D1 (de)
DK (1) DK1218027T3 (de)
ES (1) ES2338750T3 (de)
WO (1) WO2001019386A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043736D1 (de) * 1999-09-15 2010-03-11 Euclid Systems Corp Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen
KR100550385B1 (ko) * 2002-11-11 2006-02-08 메타볼랩(주) 트랜스글루타미나아제를 포함하는 칸디다 속의 미생물과그의 숙주 세포 사이의 결합 저해제
DK1638591T3 (da) 2003-05-29 2013-06-03 Univ Manchester Klasse iii slrp-agonister til reduktion af blodkardannelse
WO2008070848A2 (en) * 2006-12-07 2008-06-12 Priavision, Inc. Method and material for in situ corneal structural augmentation
US8846003B2 (en) 2008-03-27 2014-09-30 Symic Biomedical, Inc. Collagen-binding synthetic peptidoglycans, preparation, and methods of use
WO2011031948A2 (en) * 2009-09-11 2011-03-17 Euclid Systems Corporation Prevention of myopia
EA201290442A1 (ru) * 2009-12-04 2012-11-30 Юклид Системз Корпорэйшн Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека
EP2714718B1 (de) 2011-05-24 2017-01-11 Symic IP, LLC Hyaluronsäurebindende synthetische peptidoglycane, ihre herstellung und verfahren zu ihrer verwendung
BR112015022917A2 (pt) 2013-03-15 2017-07-18 Symic Biomedical Inc peptidoglicanos sintéticos componentes da matriz extracelular
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CN105535946A (zh) * 2015-12-14 2016-05-04 北京大学第一医院 转谷氨酰胺酶在加强角膜力学性质中的应用及生物制剂
EP3648774A4 (de) 2017-07-07 2021-04-21 Symic IP, LLC Synthetische biokonjugate
CN114225016B (zh) * 2021-12-02 2024-07-09 北京大学第一医院 一种用于抑制近视及圆锥角膜进展的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9101191D0 (en) * 1991-01-18 1991-02-27 Univ London Wound treatment
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
AU2893797A (en) * 1996-05-09 1997-12-05 Deutsche Gelatine-Fabriken Stoess Ag Gelatine consisting substantially of polypeptides of the collagens ii, vi, ix, x, xi, xii and xiv, process for preparing the same and use thereof
WO1999033342A1 (en) * 1997-12-30 1999-07-08 Thomas Jefferson University Method of suppressing tumor cell growth by administering decorin
DE60043736D1 (de) * 1999-09-15 2010-03-11 Euclid Systems Corp Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen

Also Published As

Publication number Publication date
KR100720291B1 (ko) 2007-05-21
EP1218027A2 (de) 2002-07-03
JP2003509376A (ja) 2003-03-11
AU7580200A (en) 2001-04-17
WO2001019386A3 (en) 2001-09-27
WO2001019386A2 (en) 2001-03-22
DK1218027T3 (da) 2010-05-10
ES2338750T3 (es) 2010-05-12
CN1214815C (zh) 2005-08-17
KR20020053060A (ko) 2002-07-04
EP1218027B1 (de) 2010-01-20
DE60043736D1 (de) 2010-03-11
CN1390133A (zh) 2003-01-08
JP2011063602A (ja) 2011-03-31
JP4786095B2 (ja) 2011-10-05

Similar Documents

Publication Publication Date Title
DE60043736D1 (de) Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen
US5596011A (en) Method for the treatment of macular degeneration
US6946440B1 (en) Composition for stabilizing corneal tissue during or after orthokeratology lens wear
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
ES2160704T3 (es) Tratamiento del sindrome de insensibilidad parcial a la hormona de crecimiento.
BR9307077A (pt) Processo para ajuste do formato da córnea de um olho e anel corneal intra-estromático
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
CA2071629A1 (en) Use of insulin sensitizing agents to treat hypertension
BR0115208A (pt) Tratamento aperfeiçoado
SE9201573D0 (sv) Use of igf-1
BR0009528B1 (pt) implante ocular para corrigir presbiopia em olhos fÁquicos.
JP2021181472A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
Irak et al. Posner-Schlossman syndrome and nonarteritic anterior ischemic optic neuropathy
GB2111387B (en) Compositions for treating glaucoma
Mather et al. The efficacy of 0.75% bupivacaine with pH adjustment and hyaluronidase for peribulbar blockade: the incidence of prolonged ptosis
EP1417970A2 (de) Antiallergische, antibakterielle und rötungsmindernde Augenzusammensetzung
KR930702015A (ko) 각막 장해 치료제
ANTIMICROBIANOS CATIONIC ANTIMICROBIAL PEPTIDES—A FUTURE THERAPEUTIC OPTION?
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
Sivasubramaniam Mode of action of tarsorrhaphy in neuroparalytic keratitis
EA200100655A1 (ru) Способ изготовления состава местных бета-блокаторов улучшенного действия
DE69127767D1 (de) Verwendung von Hexetidin oder dessen Derivaten oder Salzen zur Herstellung einer pharmazeutischen Zusammensetzung für ophthalmische Verwendung
Cebon et al. Experience with dipivalyl epinephrine: its effectiveness, alone or in combination, and its side effects
Anand Ocular involvement in a case of scleroderma
Salminen et al. Bilateral uveitis during Serratia marcescens sepsis

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1218027

Country of ref document: EP